Study identifier:311CIL/0081
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An Open, Randomised, Parallel-Group, Multicentre Trial to Compare the Efficacy of a Stratified Treatment Regimen for Acute Migraine Attacks, in whichPatients Receive Therapy According to the Grade of their Migraine Disability at Baseline, Assessed by the MIDAS Questionnaire, with that of 2 Other Treatment Regimens, in which Patients Receive Standard Therapy that may be altered after 3 Attacks (Stepped Care) or within Individual Attacks (Staged Care).
migraine
N/A
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Dec 2013 by AstraZeneca
AstraZeneca
-
*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting ClinicalTrialTransparency@AstraZeneca.com.
*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting ClinicalTrialTransparency@AstraZeneca.com.
No locations available
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.